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µ"@!`)+$E('.!6NOCBH!=(2%!&'-0+1;!1(1!'+2!&)2#,!2%(/!('%(0(-+'K!('1($&-'.!2%&2!(2!(/!'+2!,#<3(,#1!*+,!CB/#)#$-'!>#1(&2#1!+32/(1#B('!/(.'&)('.!+*!!GB('2#.,('!1#4#'1#'2!,+))('.!2+!&,,#/2@!!R#/2#,'!0)+2!&'&);/(/!+*!6"7!);/&2#/!(>>3'+4,#$(4(2&2#1!&.&('/2!AW6B/#)#$-'!,#:#&)#1!2%&2!O"LBHUVU!&2!^@\!_"!('%(0(2/!AB/#)#$-'!,#$+.'(-+'!+*!/C#D!+'!CB/#)#$-'!0;!]VUa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`)+$E('.!&,,#/2!&'1!&$-:&-+'!+*!1+='/2,#&>!&1%#/(+'!,#$#42+,/!+'!)#3E+$;2#/!0;!O"LBHUVU!5,(:(4&'/#)8!>&;!4)&;!&'!(>4+,2&'2!,+)#!('!(2/!,#4+,2#1!$)('($&)!0#'#X2!*+,!2%#!2,#&2>#'2!+*!:&/+B+$$)3/(:#!$,(/(/!('!/($E)#!$#))!4&-#'2/@!!

J0/2,&$2!

GMI-1070 (rivipansel) inhibits E-selectin recognition of sialyl LewisX expressed on L-selectin and blocks integrin activation and arrest of human neutrophils.

Scott I Simon1, Vasilios A Morikis1, Shannon Chase1, and John L. Magnani2 1UC Davis Biomedical Engineering, 2Glycomimetics Inc. MD

"3)-/2#4!4,+$#//!+*!,#$,3(2>#'2!(/!('(-&2#1!0;!,+))('.!&'1!/#)#$-'!>#1(&2#1!/(.'&)('.!+*!FGB('2#.,('!1#4#'1#'2!6"7!&,,#/2!

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

I()(44(!"ZK!"#$%&'(/>!+*!Z(&4#1#/(/b!L>4+,2&'$#!+*!2%#!Y,&'/$#))3)&,!T+32#!5GUH^8!!"#$%&'()*%)+,,-%./.01)

c&/$3)&,!>(>#-$B$%(4!2+!<3&'-*;!6"7!,#$,3(2>#'2!*,+>!(/+)&2#1!6"7!3'1#,!/%#&,!

6"7!&,,#/2!&'1!2,&'/>(.,&-+'!+'!('?&>#1!#'1+2%#)(3>!(/!('%(0(2#1!0;!O"LBHUVU!

Glass Coverslip

VCAM-1

PDMS Chamber

Reservoir Syringe Pump

CD14++CD16- CD14++CD16+ CD14+CD16++

CD14:FACS

% o

f Max

CD14: Calibration CD14: On Chip

CD14+

CD14++

FACS MFI

On

Chi

p M

FI

FACS MFI

•! HUU!dC!+*!4,(>&,;! (/+)&2#1!%3>&'!6"7!+02&('#1! *,+>!:#'(43'$23,#!=&/!/%#&,#1!+:#,!AB/#)#$-'WLMJ"BH!&2!&!=&))!/%#&,!/2,#//!+*!G!1;'#/W$>G@!

•! L/+)&2#1!%3>&'!6"7/!=#,#!4#,*3/#1!+:#,!LCBHF1/->3)&2#1!efcAM!>+'+)&;#,/!('!&!>($,+?3(1($!?+=!$%&>0#,!&2!&!4%;/(+)+.($&)!/%#&,!/2,#//!

T+))('.!+'!AB/#)!032!'+2!6B/#)!&$-:&2#/!6"7!&,,#/2!1#4#'1#'2!34+'!,#$+.'(-+'!+*!CB/#)!

MZHgWLMJ"BH!0+'1!$)3/2#,!&'1!&1%#/(:#!$+'2&$2!*+,>&-+'!&,#!('%(0(2#1!0;!O"LBHUVU!0)+$E('.!+*!CB/#)#$-'!/(.'&)('.!

•! O"LBHUVUK!&!.);$+>(>#-$!/C#D!&'&)+.!1#/(.'#1!2+!('%(0(2!)#3E+$;2#!&1%#/(+'!&'1!('?&>>&-+'!2%,+3.%!0('1('.!2+!2%#!)#$-'!1+>&('!+*!AB/#)#$-'K!('%(0(2/!,#$+.'(-+'!+*!6NOCBH!&'1!2+!&!.,#&2#,!#D2#'2!CB/#)#$-'@!

•! AB/#)#$-'!$)3/2#,('.!+*!CB/#)#$-'!+'!&!,+))('.!6"7!3'1#,!/%#&,!?+=!(/!'#$#//&,;!&'1!/3S$(#'2!2+!/(.'&)!&$-:&-+'!+*!CIJBH!&'1!0+'1!*+,>&-+'!2+!LMJ"BH@!

•! O"LBHUVU!&'2&.+'(Q#/!AB/#)#$-'!,#$+.'(-+'!+*!/C#D!#D4,#//#1!+'!CB/#)#$-'!&'1!'+2!6NOCBH@!

•! 6NOCBH!&'1!CB/#)#$-'!$+B)+$&)(Q#!+'!6"7!13,('.!,+))('.!+'!AB/#)#$-'K!032!CB/#)#$-'!&)+'#!2,&'/13$#/!+32/(1#B('!/(.'&)('.!2%&2!)#&1/!2+!CIJBH!1#4#'1#'2!&,,#/2@!

•! AB/#)#$-'!0('1('.!2+!6NOCBH!>#1(&2#/!2#2%#,('.!&'1!,+))('.K!2%#,#0;!('$,#&/('.!2%#!6"7!h!&:&()&0)#!2+!0#!&$-:&2#1!0;!CB/#)#$-'!&'1!&,,#/2!:(&!CIJBHWLMJ"BH!0+'1/@!!

•! e(.%!&S'(2;!MZHg!$)3/2#,/!&'1!$+'2&$2!&,#&!&,#!/(.'(X$&'2);!,#13$#1!=%#'!CB/#)#$-'!/(.'&)('.!(/!0)+$E#1@!

M+'$)3/(+'/!

!!H@! R3'!Y@!#2!&)@K!5GUHi8@!j6%&/#!H!/231;!+*!2%#!AB/#)#$-'!('%(0(2+,!O"LBHUVU!('!4&-#'2/!=(2%!/($E)#!$#))!

&'#>(&@k!6C+N!P'#!l5HU8b#HHH^lU!G@! M%&/#K!N@!Z@K!#2!&)@!5GUHG8@!mAB/#)#$-'!)(.&'1/!&/!>#$%&'+/#'/(-:#!,#$#42+,/!+'!'#32,+4%()/!('!%#&)2%!

&'1!1(/#&/#@m!J''!`(+>#1!A'.!iU5i8b!gilBg\l@!n@! N2&12>&''K!J@K!#2!&)@!5GUHn8@!mY%#!6NOCBHBCB/#)#$-'!/(.'&)('.!$+>4)#D!,#.3)&2#/!'#32,+4%()!&1%#/(+'!

3'1#,!?+=@m!o!AD4!"#1!GHU5HH8b!GHVHBGHgU@!i@! N(>+'K!N@!L@K!#2!&)@!5GUUU8@!m7#32,+4%()!2#2%#,('.!+'!AB/#)#$-'!&$-:&2#/!0#2&!G!('2#.,('!0('1('.!2+!

LMJ"BH!2%,+3.%!&!>(2+.#'B&$-:&2#1!4,+2#('!E('&/#!/(.'&)!2,&'/13$-+'!4&2%=&;@m!o!L>>3'+)!H^i5g8b!inigBin\g@!

Y%(/!=+,E!=&/!*3'1#1!('!4&,2!0;!JLiVGli!2+!NLN!!

T#*#,#'$#/WJ$E'+=)#1.>#'2/!

L>>3'+4,#$(4(2&-+'!+*!CB/#)#$-'K!032!'+2!6NOCBHK!(/!0)+$E#1!0;!O"LBHUVU!

J$-:&-+'!+*!MZHg!:(&!pB)('E('.!AB/#)#$-'!(/!0)+$E#1!('!4,#/#'$#!+*!O"LBHUVU!

=>0-/-()"15$%00/."?-$1

•! Y,#&2>#'2!+*!AB/#)#$-'!=(2%!O"LBHUVU!&'2&.+'(Q#/b!!! CB/#)#$-'!,#$+.'(-+'!q!$)3/2#,('.K!032!'+2!6NOCBH!!!! e(.%!&S'(2;!5eJ8!MZHg!$)3/2#,!h!&'1!$+'2&$2!&,#&!*+))+=('.!&,,#/2!:(&!CIJBH!

•! @2,0-1!A!!1(/.".(,/1#$.,/10'78-(#B010-$'C1D+!>EFGF1(%"(-"#$,)%"1,H-$1."I'0.%"1

N($E)#!M#))!Z(/#&/#!4&-#'2/!('*3/#1!=(2%!O"LBHUVU!/%+=!1#$,#&/#1!6"7!,#$,3(2>#'2!

0 2 4 6 80

200

400

600

800

1000 ArrestTEM

Time (min)

PMN/

mm

2

0 12 26 38 54 660

500

1000

1500

ArrestTEM

GMI-1070 Concentration (µM)

PMN/

mm

2

!"#$%&'"%(&)*)()+,&-./01232&)*4#%)"* 5+()6*(&1&78.9 5+()6*(&:&78.9 5+(6)*(&;&78.9 5+(6)*(&<&78.9

2&="#$% 2>22 2>22 2>22 2>222>?&="#$% 12@>:? A;>AA A;>A; @B>?::&="#$% 3B>1< ??>@< @A>?: @;>1<<&="#$% ?3>B; <@>2? <@>:A <1>2AB&="#$% <3>A: ;1>2< :?>A; ;B>A?:<&="#$% ;:>:; 1;>:B 12><@ ;@>12<B&="#$% ?><3 1>;3 2>B< A>;2

0 20 40 600

100

200

300

400

500

600

700

Patient 1Patient 2Patient 3Patient 4

y = (-4.46±1.21)x+290.2y = (-6.15±1.94)x+472.3y = (-8.27±4.09)x+627.4y = (-4.24±0.95)x+304.4

Serum GMI-1070 (µM)

Arre

sted

PM

N(P

MN

/mm

2 )

20 30 40 50-200

-100

0

100

200

300201 8hr203 8hr204 8hr205 8hr

p = 0.0558r2 = 0.8916

8hr

Serum GMI-1070 at 8 hrs [uM]

Activ

ated

CD

18 [%

bas

elin

e]

J-$'C1D+!>EFGF1,#1K12$015d"8!

:.L2

1MN

".#;

154E

K11

5a!0&/#)('#8!

•! L':#,/#! $+,,# )&-+'! 1#2#$2#1!0#2=##'! rO"LBHUVUsK! 6"7! &,,#/2K!&'1!('13$-+'!+*!%(.%!&S'(2;!MZHg!

0

20

40

60Extended ($)High (#)

E-Selectin Crosslinker

GMI-1070 (100 µM) IL-8 (10 µM)

----

---+

++--

+++-

+---

$#

$#

$ $

CD

18 A

ffini

ty(R

ecep

tor x

103 )

IgG

PSGL-1L-se

l

PSGL-1+L-se

l0

20

40

60

80

100

#

##

$$

$$

E-selectin

Antibody Blocking

PMN

Adhe

sion

(# F

OV

/min

ute)

IgG

PSGL-1L-se

l

PSGL-1+L-se

l0

20

40

60

80

100

###

Rolling (#)Arrest ($)

###

P-selectin

Antibody Blocking

PMN

Adhe

sion

(# F

OV

/min

ute)

•! T+))('.!+'!AB/#)#$-'WLMJ"BH!(/!/344+,2#1!0;!0+2%!CB/#)#$-'!&'1!6NOCBH!•! T+))('.!+'!6B/#)#$-'!(/!6NOCBH!1#4#'1#'2!&'1!1+#/!'+2!('13$#!&,,#/2!•! J$-:&-+'!+*!&,,#/2!(/!('%(0(2#1!0;!&'-BCB/#)!&'1!'+2!&'-B6NOCBH!

Vehi

cle

GM

I-107

0

GSn

P-6

Unt

reat

ed

GM

I-107

0

GSn

P-6

0

500

1000

1500

2000

Treatment:

***

**

***

*

L-se

lect

in C

onte

nt(R

elat

ive

Den

sity

)

Vehi

cle

GM

I-107

0

GSn

P-6

Unt

reat

ed

GM

I-107

0

GSn

P-6

0

5000

10000

15000

20000

***

** ***

***

Treatment:

PSG

L-1

Con

tent

(Rel

ativ

e D

ensi

ty)

E.

Treatment:

D.

69 kDa -

120 kDa -

210 kDa -

- GMI-1070 GSnP-6 - GMI-1070 GSnP-6IP: E-selectin P-selectin

L-selectinMonomeric PSGL-1Dimeric PSGL-1

•! AB/#)#$-'!(>>3'+4,#$(4(2&2#/!0+2%!CB/#)#$-'!&'1!6NOCBH!•! O"LBHUVUK!032!'+2!ON'6B^K!0)+$E/!AB/#)#$-'!43))!1+='!+*!CB/#)#$-'!•! ON'6B^!0)+$E/!6B/#)#$-'!43))!1+='!+*!6NOCBH!2+!&!.,#&2#,!#D2#'2!2%&'!O"LBHUVU!

O"LBHUVU!('%(0(2/!&$-:&-+'!+*!6"7!&,,#/2!13,('.!,+))('.!+'!(>>+0()(Q#1!AB/#)#$-'WLMJ"BH!

0.1 6.5 19.5 100 0.1 12 36 1200

20

40

60

80

100

120

ArrestRolling

GMI-1070 GSnP-6

****

Treatment (µM):PM

N Ad

hesi

on(%

Tot

al In

tera

ctio

n)

0 2 4 6 8 10 120

20

40

60

80

100

VehicleGMI-1070GSnP-6

***

Rolling Velocity (µm/s)

PMN

Rolli

ng(%

)

•! CB/#)#$-'! /(.'&)('.! (/! '#$#//&,;! &'1! /3S$(#'2! 2+! ('13$#! FGB('2#.,('WLMJ"BH!>#1(&2#1!X,>!&,,#/2!+*!6"7!,+))('.!+'!AB/#)#$-'!

•! 6"7!,+))('.!:#)+$(2;!(/! ('$,#&/#1!0;!O"LBHUVU!+,!ON'6B^!0)+$E('.!1(/-'$2!/(2#/!+'!2%#!)#$-'!1+>&('!+*!AB/#)#$-'!

•! ON'6B^! *3'$-+'/! &/! &! 6NOCBH! >(>#-$! 2+! &'2&.+'(Q#! ,+))('.K! =%#,#&/! O"LBHUVU!0)+$E/!,#$+.'(-+'!+*!CB/#)#$-'!&'1!FGB('2#.,('!>#1(&2#1!&,,#/2!

Vehicle GMI-1070 GSnP-60

5

10

15

**

Rolling to Arrest

Treatments:

HA C

D18

Clu

ster

s(#

Site

s/PM

N)

Vehicle GMI-1070 GSnP-60

1

2

3

4

***

Arrested

Treatments:

CD

18 A

rea

(µm

2 /PM

N)

•! ZL! >#>0,&'#! 1;#! ('2#'/(2;!4,+:(1#1!>#&/3,#!+*!%#(.%2!

•! C B /# ) # $-'! &'1! 6NOC BH!*++24, ('2! (>&.#1! =( 2%!1(/$,#2#! ?3+,+4%+,#/! 3/('.!GB)('#!<ZI!